Skip to main content
MyDeficiencies

Toremifene

SERM, triphenylethylene / anti-estrogen

Also sold as Fareston.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Toremifene is not a classical depletion drug. It is extensively metabolized hepatically by CYP3A4 (with auto-induction of its own clearance on prolonged dosing), it is over 99.5% protein-bound, its absorption is unaffected by food, and it is eliminated almost entirely as metabolites in feces, with only about 10% appearing in urine and no described effect on renal tubular handling of electrolytes or water. There is no chelation, no gastric-pH-dependent absorption mechanism, and no renal-wasting pathway in the label or in the literature searched for this review. Toremifene is chemically a chlorinated derivative of tamoxifen (both are nonsteroidal triphenylethylenes) and the two drugs are frequently studied head-to-head, which this review used deliberately: every class-level lead borrowed from tamoxifen's own dossier was independently re-opened and re-verified here before being used. This revision closes two categories that a prior tooling-limited pass had left ungraded: a tamoxifen-class mouse NCOA4/erythroid-toxicity letter was independently re-opened in full this session, and a tamoxifen-class isolated-mitochondria oxidative-phosphorylation paper (Cardoso et al., Toxicology, 2002) was independently confirmed at title, journal, author and DOI level this session, though its abstract text itself remained blocked by a PubMed bot check throughout this review and so is not quoted quantitatively here.

SERM, triphenylethylene / anti-estrogen · ATC L02BA02 · also sold as Fareston · reviewed 2026-09-26. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Toremifene in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

LDL cholesterol / lipid metabolism, consistent, mechanistically-explained reduction across two independent human trials

Red — Severe

See study details

Toremifene lowers serum LDL and total cholesterol by roughly 15-16% over 12 months to 3 years in two independent randomized trials, through a named, drug-specific mechanism; this is a real, reverse-direction (protective) lipid effect, not a nutrient deficiency, and no supplementation is implied by it.

Full detail, limits and 6 references

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. red

Limits on what this shows

  • Key negative / null findings: Neither trial found a significant change in triglycerides at standard dosing; the FDA label's postmarketing section separately reports hypertriglyceridemia (case-level, not incidence-quantified), so triglycerides specifically should not be assumed to move the same protective direction as LDL. Corroborating title-level evidence exists but was not independently opened beyond a PubMed search-listing snippet, and is disclosed as such rather than used to add quantitative weight: Kusama et al., Breast Cancer Res Treat 2004 (PMID 15538040, direct toremifene-versus-tamoxifen serum lipid comparison, 1-year, postmenopausal Japanese patients); Anan et al., Breast Cancer Res Treat 2011 (PMID 21638048, toremifene versus anastrozole, 2-year, serum lipids and bone metabolism); Chi et al., Breast Cancer 2013 (PMID 23266963, meta-analysis, toremifene associated with greater triglyceride decrease than tamoxifen); Smith et al., J Clin Oncol 2008 (PMID 18398147, toremifene 8.2% LDL reduction, but in men on androgen-deprivation therapy for prostate cancer, a different population and indication than the labeled use).
  • At-risk subgroups: None identified for the protective direction; patients with baseline hypertriglyceridemia are the group in whom the separate, unquantified postmarketing hypertriglyceridemia signal would matter most, consistent with the general SERM triglyceride caution documented for tamoxifen.

Regulatory status

Not framed as a benefit in the FDA label; the label's postmarketing section separately notes hypertriglyceridemia has been reported, so the lipid picture is not uniformly favorable across all lipid fractions (see counter-evidence below).

Population evidence

(1) Gylling et al., J Clin Oncol 1995, n=24 postmenopausal Finnish women with advanced breast cancer (drawn from a larger 415-patient international trial), randomized to tamoxifen or toremifene 12 months: both drugs significantly reduced LDL cholesterol 15-16% with no significant change in HDL or triglycerides; serum delta-8-cholestenol rose 40-55-fold while lathosterol showed minimal change, indicating inhibition of the delta-8-sterol-isomerase step of cholesterol synthesis. PMID 8523053. (2) Saarto et al., J Clin Oncol 1996, randomized trial, n=49 postmenopausal women with node-positive breast cancer, tamoxifen 20 mg/day (n not toremifene-specific in this citation) versus toremifene 60 mg/day for 3 years: both drugs significantly reduced total and LDL cholesterol and apolipoprotein B; toremifene specifically raised HDL cholesterol 14% while tamoxifen lowered it 5% (between-drug difference P=.001), giving toremifene a more favorable cholesterol-to-HDL and LDL-to-HDL ratio change; both drugs similarly reduced lipoprotein(a). PMID 8636753.

Mechanism

Named and drug-specific: inhibition of the delta-8-cholesterol isomerase enzyme step in endogenous cholesterol biosynthesis, directly evidenced by the 40-55-fold rise in the precursor delta-8-cholestenol in the Gylling study, reducing hepatic cholesterol synthesis and secondarily lowering circulating LDL.

Counter-evidence held on record

This is a protective lipid-metabolism effect, not a nutrient deficiency, and must never be presented as license to skip lipid monitoring or as a reason to add or remove any supplement. Triglycerides specifically are not shown to move in this same favorable direction and have a separate, unquantified postmarketing signal in the other direction.

Calcium, hypercalcemia and tumor flare, bounded to bone-metastasis patients in the first weeks of therapy

Orange — Moderate

See study details

Toremifene can raise serum calcium in breast cancer patients with bone metastases, concentrated in the first weeks of treatment; this is a labeled, drug-attributed excess-risk effect, not a calcium deficiency, and calcium supplementation would be the wrong response to it.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative / null finding: The Nordic clinical trial recorded zero hypercalcemia events, and the Eastern European trial recorded only one (<1%), against 3% in the North American trial, indicating the effect is real but inconsistent in frequency across trial populations rather than a fixed, universal risk.
  • At-risk subgroups: Breast cancer patients with bone metastases specifically; not described as a risk in patients without bone involvement.

Regulatory status

FDA label, Warnings and Precautions: "As with other antiestrogens, hypercalcemia and tumor flare have been reported in some breast cancer patients with bone metastases during the first weeks of treatment." Clinical-trial incidence: North American study 6/≈200 patients (3%); Eastern European study 1 patient (<1%); Nordic study 0 patients. FDA label / DailyMed.

Population evidence

Directly measured serum calcium elevation, drug-attributed by the label itself, in the pivotal registration trials for toremifene in metastatic breast cancer, bounded to the subgroup with pre-existing bone metastases and to the first weeks of exposure.

Mechanism

Tumor flare: transient estrogen-agonist stimulation of tumor and osteoclast activity at bone-metastatic sites early in antiestrogen therapy, releasing calcium from bone into circulation; the label frames this as a class effect shared with other antiestrogens (that is, toremifene is not uniquely implicated, but it is directly implicated).

Counter-evidence held on record

This is an excess/retention risk, not a deficiency. Calcium (or vitamin D) supplementation should never be recommended on the basis of toremifene use; the correct clinical response to this entry is serum calcium monitoring in bone-metastasis patients early in therapy, not calcium intake changes, and no dose is implied by this entry.

Potassium, direction correction

Yellow — Low

See study details

Toremifene's label requires hypokalemia be corrected before starting therapy and monitored periodically because low potassium increases the risk of Torsade de pointes on top of toremifene's own dose-dependent QT prolongation; there is no evidence toremifene itself lowers serum potassium, and this entry exists to correct the direction, not to report a depletion.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: No toremifene-specific renal-potassium-wasting or GI-potassium-loss mechanism exists in the literature searched for this review; the absence itself is the finding.
  • At-risk subgroups: Patients with any cause of baseline hypokalemia (diuretic use, GI losses, poor intake) starting toremifene, because of the additive Torsade de pointes risk, not because toremifene will worsen their potassium status.

Regulatory status

FDA label, Warnings and Precautions: "Hypokalemia or hypomagnesemia must be corrected prior to initiating toremifene and these electrolytes should be monitored periodically during therapy." No frequency data for hypokalemia as an adverse event are given in the label, and no mechanism by which toremifene would lower serum potassium (renal wasting, GI loss, aldosterone-axis effect) is described anywhere in the label or in the literature searched for this review.

Population evidence

No study measuring toremifene's effect on serum potassium status was located. A consumer-facing monograph (drugs.com, accessed 2026-09-26) frames uncontrolled hypokalemia as a contraindication to starting toremifene, consistent with the label's framing: the electrolyte status gates whether the drug is safe to start, not the reverse.

Mechanism (direction check, Hard Rule 4)

The documented relationship is potassium status affecting toremifene's arrhythmia risk, not toremifene affecting potassium status. This is filed as a monitoring/timing requirement rather than a depletion mechanism.

Overlap

Shares its evidentiary source (the same label warning statement) with the Magnesium entry below; see Overlap map.

Counter-evidence held on record

This is not a depletion finding and potassium supplementation should never be recommended on the basis of toremifene use alone. The correct action is baseline and periodic serum potassium monitoring and correction of any pre-existing hypokalemia before and during therapy, coordinated with a prescriber.

Magnesium, direction correction

Yellow — Low

See study details

Toremifene's label requires hypomagnesemia be corrected before starting therapy and monitored periodically for the same Torsade de pointes reason as potassium; there is no evidence toremifene itself lowers serum magnesium, and this entry exists to correct the direction, not to report a depletion.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: No toremifene-specific renal-magnesium-wasting mechanism exists in the literature searched for this review; the absence itself is the finding.
  • At-risk subgroups: Patients with any cause of baseline hypomagnesemia starting toremifene, because of the additive Torsade de pointes risk, not because toremifene will worsen their magnesium status.

Regulatory status

FDA label, Warnings and Precautions: same sentence as the Potassium entry, "Hypokalemia or hypomagnesemia must be corrected prior to initiating toremifene and these electrolytes should be monitored periodically during therapy." No frequency data for hypomagnesemia as an adverse event are given, and no renal-wasting, GI-loss, or other depletion mechanism for magnesium is described anywhere in the label or the literature searched for this review.

Population evidence

No study measuring toremifene's effect on serum magnesium status was located. The same consumer-facing monograph checked for the Potassium entry frames uncontrolled hypomagnesemia as a contraindication to starting toremifene, not as an effect of the drug.

Mechanism (direction check, Hard Rule 4)

The documented relationship is magnesium status affecting toremifene's arrhythmia risk, not toremifene affecting magnesium status. Filed as a monitoring/timing requirement, not a depletion mechanism.

Overlap

Shares its evidentiary source (the same label warning statement) with the Potassium entry above; see Overlap map.

Counter-evidence held on record

This is not a depletion finding and magnesium supplementation should never be recommended on the basis of toremifene use alone. The correct action is baseline and periodic serum magnesium monitoring and correction of any pre-existing hypomagnesemia before and during therapy, coordinated with a prescriber.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, disrupted membrane potential across two independent toremifene-specific in vitro sources

Yellow — Low

See study details

In human vascular smooth muscle cells, toremifene disrupted mitochondrial membrane potential and triggered apoptosis through the mitochondrial signaling pathway, and a second, independently-opened 2024 mitochondrial-toxicity screen of 45 drugs found toremifene was one of only four that altered mitochondrial swelling, transmembrane potential and reactive oxygen species together in isolated mouse liver mitochondria; both are real, drug-specific in vitro findings, and neither has been measured in a living human.

Full detail, limits and 4 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: This is a single in vitro study; no human systemic marker of mitochondrial function in toremifene-treated patients was found in this review, positive or negative, which is the evidence gap rather than a null result. A separate, toremifene-inclusive rat hepatocarcinogenicity study (Hirsimäki et al., Arch Toxicol 1993;67(1):49-54, PMID 8452480, confirmed via indexed metadata as directly comparing tamoxifen and toremifene over 1 year) could not have its full abstract retrieved during this review and is not used as supporting evidence here; toremifene's own FDA label carcinogenicity section, by contrast, reports no evidence of carcinogenicity in a 2-year rat study at doses spanning roughly half to twice the human maximum recommended dose, an apparent difference from the older animal literature that this review could not resolve from primary text and discloses rather than adjudicates.
  • At-risk subgroups: Not established in humans; concentration-response detail (specific micromolar concentrations tested) could not be retrieved from the available text of this paper during this review.

Regulatory status

Not addressed in the FDA label.

Population evidence

Wang et al., "The adverse effect of anticancer drug toremifene on vascular smooth muscle cells is an important aspect of its tumor growth inhibition," J Cancer Res Clin Oncol 2023;149(10):7837-7848. In vitro, human aortic vascular smooth muscle cells (HAVSMCs) treated with toremifene (TOR): toremifene "disrupted intracellular reactive oxygen species and mitochondrial membrane potential" and "induced apoptosis by the mitochondrial signaling pathway," with enhanced p53 expression and increased caspase-3 and caspase-9 activity. The paper additionally reports toremifene damaging the cytoskeleton through the Rho/ROCK pathway. DOI 10.1007/s00432-023-04744-9, PMID 37036506. Independently re-opened this session, full abstract text confirmed: Buron N, Porceddu M, Loyant R, et al., "Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals," Toxicol Sci 2024;200(2):369-381. Isolated mouse liver mitochondria, tri-parametric mitochondrial fatty-acid-oxidation (mtFAO) assay across 45 drugs (32 steatogenic, 13 nonsteatogenic): "only amiodarone, ketoconazole, lovastatin, toremifene altered all these 3 mitochondrial parameters" (swelling, transmembrane potential, reactive oxygen species production), a broader toxicity profile than most of the 45 drugs screened. DOI 10.1093/toxsci/kfae055, PMID 38676573.

Mechanism

Named and drug-specific: mitochondrial membrane potential collapse with downstream caspase-9/caspase-3 (intrinsic/mitochondrial apoptotic pathway) activation and p53 upregulation, proposed by the authors as the route by which toremifene damages the vascular smooth muscle cells that support tumor blood supply.

Overlap

Shares its HAVSMC evidentiary source with the Oxidative stress entry below, and shares its Buron et al. 2024 evidentiary source with both the Oxidative stress and ATP production entries; see Overlap map.

Counter-evidence held on record

No supplement or cofactor dose is implied by this entry. This is a single in vitro, non-cardiac-myocyte cell-type finding intended by its own authors to explain toremifene's anti-tumor vascular effect, not a demonstrated mitochondrial deficiency syndrome in patients at the approved 60 mg/day dose.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, reactive oxygen species increase across two toremifene-specific in vitro sources, opposite direction from tamoxifen's own systemic antioxidant signal

Yellow — Low

See study details

The same human vascular smooth muscle cell study that found mitochondrial membrane potential disruption also found toremifene raised intracellular reactive oxygen species, and a second, independently re-opened 2024 isolated-mitochondria screen confirms toremifene alters reactive oxygen species production as part of a broader mitochondrial toxicity profile; this is a real, pro-oxidant, in vitro finding across two sources, and stands in contrast to a published systemic antioxidant effect for the structurally related drug tamoxifen at standard clinical dosing.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: This review independently re-verified (not cited secondhand) that tamoxifen, toremifene's close structural analog, was directly measured to lower lipid peroxidation and raise circulating antioxidant capacity (selenium, vitamins A/C/E) in postmenopausal breast cancer patients over 6 months of standard-dose therapy in a separate, unrelated human study; toremifene has no equivalent human systemic measurement, and the one direct toremifene finding available (this vascular-cell study) points the opposite, pro-oxidant direction. The two findings are not directly comparable (different species of measurement: systemic human circulating markers for tamoxifen versus a single in vitro vascular cell line for toremifene) but the discordance is disclosed rather than smoothed over, since toremifene and tamoxifen are frequently assumed interchangeable by patients and clinicians.
  • At-risk subgroups: Not established in humans.

Regulatory status

Not addressed in the FDA label.

Population evidence

Wang et al. 2023 (see Mitochondrial burden entry, same source): toremifene "disrupted intracellular reactive oxygen species" in human aortic vascular smooth muscle cells in vitro, alongside mitochondrial membrane potential collapse and mitochondrial-pathway apoptosis. PMID 37036506. Independently re-opened this session: Buron et al. 2024 (see Mitochondrial burden entry, same source), isolated mouse liver mitochondria, toremifene one of only four of 45 screened drugs whose reactive-oxygen-species production was altered alongside mitochondrial swelling and transmembrane potential. DOI 10.1093/toxsci/kfae055, PMID 38676573.

Mechanism

Not separated from the mitochondrial-disruption mechanism in the retrievable text of this paper; reactive oxygen species generation is presented as part of the same mitochondrial-membrane-potential-collapse cascade rather than as an independently driven redox effect.

Overlap

Shares both its evidentiary sources with the Mitochondrial burden entry above, and shares its Buron et al. 2024 source with the ATP production entry below; see Overlap map. Do not count these as fully independent confirmations of toremifene mitochondrial/oxidative toxicity beyond the two underlying experiments.

Counter-evidence held on record

Do not extrapolate tamoxifen's systemic antioxidant finding onto toremifene; the one direct toremifene data point available runs the other way. No antioxidant supplement dose is implied or recommended by this entry in either direction.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No toremifene-specific literature on copper status, ceruloplasmin, or copper-dependent enzymes was located at any evidence tier in a fresh, from-scratch search this session, and no circulating consumer claim about toremifene and copper was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded are met, re-confirmed this session rather than carried forward. Fresh PubMed search-listing queries this session for "toremifene copper" and "toremifene AND (copper OR cuproptosis OR ceruloplasmin)" returned either a large unrelated result set (general cancer/copper/cuproptosis biology, no toremifene-specific hit among the top results) or were themselves blocked by a bot check on retry. No consumer source checked (drugs.com, RxList) mentions copper in connection with toremifene. This matches the conclusion of the prior review but rests on independently repeated searches, not on that review's reasoning.

Tooling note

PubMed's search-listing pages were reachable for at least one full attempt this session and returned genuine, readable, unrelated result sets (not a block page), supporting a real literature gap rather than a tooling failure specific to copper. Crossref, OpenAlex's search endpoint, Europe PMC and the Semantic Scholar Graph API were each attempted this session and each returned HTTP 429 throughout (see access note in Sources); a future revision should re-try those specific channels for copper before treating this gap as fully exhausted.

Iron

Not graded — disclosed evidence gap

See study details

No toremifene-specific literature on iron status, ferritin, hepcidin, or ferroptosis was located at any evidence tier in a fresh, from-scratch search this session, and no circulating consumer claim about toremifene and iron was found to rebut as white.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded are met, re-confirmed this session. A fresh, dedicated PubMed search-listing query this session, "toremifene AND (iron OR ferritin OR hepcidin OR ferroptosis)," returned a result count of zero ("No results were found"), a clean negative rather than a blocked page. This is a genuinely independent result from this session, not a repetition of the prior review's search. No consumer source mentioned iron in connection with toremifene. Note that a toremifene-specific 2024 isolated-mitochondria screen (see ATP production and Mitochondrial burden entries) measured mitochondrial parameters relevant to ferroptosis biology but did not report iron, ferritin, or hepcidin data specifically, so it does not change this entry's grade.

Tooling note

Same as the Copper entry: the PubMed search-listing page returned a genuine, readable, zero-result page this session, supporting a real gap rather than a blocked search. Crossref, OpenAlex's search endpoint, Europe PMC and Semantic Scholar were each attempted this session and each returned HTTP 429; a future revision should re-try those channels for iron specifically.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, class extrapolation only, toremifene itself not directly studied

Yellow — Low

See study details

No toremifene-specific human or animal gut-microbiome study exists at any tier; this entry is graded yellow purely on class extrapolation from a directly re-verified human cohort study of tamoxifen, a chemically near-identical SERM, and should not be read as toremifene-specific evidence.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: Even in the tamoxifen cohort, overall microbial diversity and community structure (Shannon index, PERMANOVA) did not change significantly; only specific taxa shifted. A dedicated, multi-phrasing PubMed search for "toremifene gut microbiome," "toremifene microbiota," and "toremifene gut flora" returned zero toremifene-specific results.
  • At-risk subgroups: Not established for toremifene. The tamoxifen cohort was exclusively postmenopausal ER+/HER2- patients.

Regulatory status

Not addressed in the FDA label.

Population evidence

None for toremifene. Class-level source, independently re-opened and re-verified in this review (not cited secondhand): a prospective cohort of 62 postmenopausal ER+/HER2- breast cancer patients across three Dutch hospitals, 60 paired fecal samples before and 6-12 weeks into tamoxifen therapy specifically (toremifene was not part of this cohort). ASV richness increased significantly (P=0.0188); Shannon diversity index was unchanged (P=0.166); specific genera shifted significantly ( Blautia, Streptococcus, Eubacterium hallii group and others increased; Prevotella_9 and Subdoligranulum decreased), while overall community structure remained stable. PMC11885672.

Mechanism

Not established for toremifene. For tamoxifen, no drug-microbiome mechanism was tested in the human cohort itself; this review did not independently re-verify the separate mouse bile-acid/FXR mechanistic paper cited in tamoxifen's own dossier and so does not repeat that mechanistic claim here.

Counter-evidence held on record

This entry exists to flag a plausible, class-level concern, not to assert that toremifene itself disrupts the gut microbiome. It should always be presented with the class-extrapolation caveat and should be revisited if a toremifene-specific microbiome study is ever published.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production, toremifene-specific mitochondrial fatty-acid-oxidation impairment in isolated mitochondria, plus tamoxifen-class oxidative-phosphorylation uncoupling

Yellow — Low

See study details

Toremifene was one of only four of 45 drugs to alter mitochondrial swelling, transmembrane potential and reactive oxygen species together in an isolated mouse liver mitochondria fatty-acid-oxidation assay, a broad mitochondrial toxicity profile mechanistically upstream of oxidative-phosphorylation-driven ATP synthesis; this is not a directly measured ATP or human energy-metabolism deficit, and it resolves this entry from ungraded to yellow this session on genuinely toremifene-specific evidence rather than class extrapolation alone.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: The Buron paper is a screening study across 45 drugs precisely because most tested drugs did not show this broad three-parameter toxicity signature; toremifene's inclusion in the small four-drug positive group is notable but the paper reports no toremifene-specific dose-response curve or human correlate in the retrieved text. No toremifene-specific study measuring ATP levels, oxygen consumption, or respirometry directly (rather than the upstream mtFAO/swelling/potential/ROS parameters) was located in this or the prior review.
  • At-risk subgroups: Not established in humans; both supporting sources are isolated-mitochondria animal preparations, not measurements in toremifene-treated or tamoxifen-treated patients.

Regulatory status

Not addressed in the FDA label. The label's hepatotoxicity monitoring requirement (periodic liver function tests) is consistent with, but not directly evidence for, a mitochondrial fatty-acid-oxidation mechanism.

Population evidence

Buron N, Porceddu M, Loyant R, Martel C, Allard J, Fromenty B, Borgne-Sanchez A. "Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals." Toxicol Sci 2024;200(2):369-381. Isolated mouse liver mitochondria; mitochondrial respiration measured with palmitoyl-l-carnitine, palmitoyl-CoA plus l-carnitine, and octanoyl-l-carnitine as fatty-acid-oxidation substrates, and separately with malate/glutamate or succinate to localize the mechanism. Toremifene was tested among 32 steatogenic drugs. The tri-parametric mtFAO assay predicted clinical steatosis with sensitivity and positive predictive value above 88% across the full 45-drug panel. Toremifene was one of only four drugs, alongside amiodarone, ketoconazole and lovastatin, all established mitochondrial toxins, that altered all three secondary mitochondrial parameters (swelling, transmembrane potential, reactive oxygen species). DOI 10.1093/toxsci/kfae055, PMID 38676573, full abstract independently retrieved via OpenAlex this session. Independently re-confirmed at title, author, journal and DOI level this session (abstract text blocked by a PubMed bot check throughout this review, so its specific quantitative respiratory-control-ratio and ADP/O findings are not repeated here): Cardoso CM, Moreno AJ, Almeida LM, Custódio JB. "4-Hydroxytamoxifen induces slight uncoupling of mitochondrial oxidative phosphorylation system in relation to the deleterious effects of tamoxifen." Toxicology 2002;179(3):221-232. Isolated rat liver mitochondria; the title itself establishes tamoxifen's active metabolite uncouples oxidative phosphorylation. DOI 10.1016/s0300-483x(02)00392-x, PMID 12270594.

Mechanism

For toremifene: impairment of mitochondrial fatty-acid oxidation reduces acetyl-CoA and NADH/FADH2 delivery to the electron transport chain, and the paper's own respiratory-chain-substrate arm (malate/glutamate, succinate) was used specifically to test whether a drug's mtFAO impairment traces to respiratory-chain dysfunction or to a more direct fatty-acid-oxidation block; the retrievable abstract text groups toremifene only in the broader three-parameter (swelling/potential/ROS) toxicity class rather than assigning it to either named sub-mechanism, so which specific step toremifene affects is not fully resolved from this source. For the tamoxifen-class comparator, the named mechanism (per its title) is direct uncoupling of oxidative phosphorylation via the active metabolite 4-hydroxytamoxifen.

Overlap

Shares its Buron et al. 2024 source with the Mitochondrial burden and Oxidative stress entries above (the same 45-drug screen measured all three parameters together in one experiment); see Overlap map. The Cardoso et al. 2002 tamoxifen-class source is not shared with any other entry in this dossier.

Counter-evidence held on record

No CoQ10, creatine, ribose or other energy-metabolism supplement dose is implied by this entry in either direction. This is an isolated-mitochondria screening finding in an animal preparation, not a demonstrated clinical fatigue or ATP-deficit syndrome in toremifene-treated patients at the approved 60 mg/day dose.

Oxygen delivery / utilization, toremifene-specific hemoglobin decrease reported in a dose-finding trial, confounded by underlying malignancy, plus tamoxifen-class NCOA4 mechanistic support

Yellow — Low

See study details

A Japanese multicenter phase II dose-finding trial of toremifene in advanced or recurrent breast cancer reported hemoglobin decrease among observed adverse events at doses of 40-240 mg/day; this is toremifene-specific but confounded by indication (advanced malignancy itself commonly causes anemia) and not quantified by incidence, so this entry resolves from ungraded to yellow rather than to orange.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative / null finding: The toremifene trial reported "no clear dose-dependency" in adverse event incidence, arguing against a simple dose-driven depletion narrative. The NCOA4 mouse model used 200 mg/kg, far above the human toremifene or tamoxifen therapeutic dose range, and showed recovery of blood counts by day 21, suggesting a reversible, exposure-dependent effect in animals rather than permanent marrow injury. Confounding by indication is not excluded in the toremifene trial: all patients had advanced or recurrent breast cancer, a population in which anemia is common from disease burden alone, and there was no untreated or placebo comparator arm.
  • At-risk subgroups: Not established beyond the general advanced/recurrent breast cancer population studied in the toremifene trial; no subgroup analysis by baseline hemoglobin, marrow involvement, or concurrent chemotherapy was available in the retrieved abstract.

Regulatory status

FDA label documents leukopenia and thrombocytopenia as occurring "rarely," monitored accordingly, but this review directly re-checked the DailyMed label's adverse-reactions section this session and confirmed again that anemia, hemoglobin, and hematocrit are not mentioned anywhere in it, positive or negative. DailyMed, setid 2cab8dd1-3a10-48e6-86ce-0e5275ed49e5, re-checked 2026-09-26.

Population evidence

Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study. Gan To Kagaku Ryoho 1993;20(2), PMID 8422189 (Japanese-language journal, English-language structured abstract). Multicenter, single-arm, dose-finding trial, oral toremifene daily for more than 8 weeks at 40, 60, 120 or 240 mg/day in patients with advanced or recurrent breast cancer; objective response rates ranged 13.8-40.0% across dose cohorts with no clear dose-response pattern. Adverse events observed: "elevation of GOT, GPT, serum Ca level, decrease of hemoglobin, anorexia, nausea/vomiting, fatigue, dizziness and hot flush," characterized as "moderate in grade and reversible," with no clear dose-dependency in incidence. PMID 8422189, English abstract independently retrieved via OpenAlex this session; full Japanese-language text not accessed. Class-level mechanistic support, independently re-opened in full this session (not cited secondhand from tamoxifen's own dossier): mouse study (Sv129/J background, wild-type and Ncoa4-knockout littermates), 200 mg/kg tamoxifen by oral gavage daily for 5 days: Ncoa4-knockout mice showed significant reductions in red blood cell count, hemoglobin and hematocrit by day 4, and by day 11 wild-type mice also showed significant reductions in the same parameters, implicating NCOA4 (the ferritinophagy receptor that liberates stored iron for erythropoiesis) in the severity of SERM-associated erythroid suppression. Haematologica, correspondence/letter, independently opened at https://haematologica.org/article/view/9031.

Mechanism

Not established for toremifene beyond the observed association. The class-level NCOA4 mouse letter proposes disrupted estrogen-receptor and nuclear-receptor signaling in erythroid progenitors, with NCOA4-mediated iron handling modulating severity, a mechanism plausible for toremifene given its shared triphenylethylene SERM pharmacology with tamoxifen, but not itself demonstrated in toremifene.

Overlap

Does not overlap with any other graded entry in this dossier; the Iron entry below remains a separate, ungraded category despite the NCOA4 mechanism's link to iron handling, per Hard Rule 7 (Oxygen delivery/utilization and Iron are never merged).

Counter-evidence held on record

No iron, B12, folate or other hematinic supplement dose is implied by this entry. Anemia in a patient with advanced or recurrent breast cancer on toremifene should first be worked up for disease-related causes (marrow involvement, chronic disease, concurrent chemotherapy) before being attributed to toremifene itself, consistent with Hard Rule 6 on confounding by indication.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • No toremifene-specific nutrient-depletion claim was found circulating at all

    Where it comes from: N/A, checked directly against drugs.com and RxList consumer monographs for toremifene/Fareston, and a PubMed circulating-claim search, specifically looking for the CoQ10, B-vitamin, magnesium, zinc and vitamin-D "drug mugging" style claims that circulate widely for tamoxifen.

    Why it fails: Unlike tamoxifen, no consumer source checked in this review makes any vitamin, mineral, or supplement depletion claim about toremifene specifically. This section is genuinely near-empty rather than silently omitted: the absence of circulating claims is itself disclosed as a finding, per this project's rule that an empty section must state why it is empty rather than being left out.

All references used above
  1. FARESTON (toremifene citrate) tablets, full prescribing information. — DailyMed SPL, setid 2cab8dd1-3a10-48e6-86ce-0e5275ed49e5, Kyowa Kirin, Inc. Clinical pharmacology, warnings and precautions (QT prolongation, electrolytes, hepatotoxicity, hypercalcemia/tumor flare), drug interactions, adverse reactions, nonclinical toxicology/carcinogenesis, dosage.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, L02BA02 toremifene. — ATC classification and defined daily dose (60 mg oral) confirmation.
  3. Wang H, Liu J, Wang M, Yang C, Wang G, Hu T. The adverse effect of anticancer drug toremifene on vascular smooth muscle cells is an important aspect of its tumor growth inhibition. — J Cancer Res Clin Oncol. 2023;149(10):7837-7848. Human aortic vascular smooth muscle cells (HAVSMC), in vitro; reactive oxygen species, mitochondrial membrane potential, apoptosis (p53, caspase-3/9), Rho/ROCK cytoskeletal pathway.Full methods/results (specific concentrations, possible ATP/respirometry data) not retrievable beyond the fetched abstract/summary during this review.
  4. Gylling H, Pyrhönen S, Mäntylä E, Mäenpää H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. — J Clin Oncol. 1995;13(12):2900-2905. PMID 8523053. Randomized, n=24 postmenopausal women (subset of a 415-patient international trial), tamoxifen vs toremifene, 12 months; LDL reduced 15-16%, HDL/triglycerides unchanged, delta-8-cholestenol rose 40-55-fold.
  5. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. — J Clin Oncol. 1996;14(2):429-433. PMID 8636753. Randomized, n=49, tamoxifen 20 mg/day vs toremifene 60 mg/day, 3 years; both reduced total/LDL cholesterol and apo B; toremifene raised HDL 14% vs tamoxifen's 5% reduction (P=.001); both reduced lipoprotein(a).
  6. Marttunen MB, Hietanen PS, Tiitinen AE, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. — J Clin Endocrinol Metab. 1998;83(4):1158-1162. PMID 9543133. Randomized, n=30 (tamoxifen 20 mg/day n=16, toremifene 40 mg/day n=14), 12 months; tamoxifen increased BMD and reduced resorption markers, toremifene did not increase BMD but prevented age-related bone loss. Used as pharmacological/bone context, not as a graded nutrient entry, per Hard Rule 2 (a bone-density change is a clinical outcome, not a measured calcium or vitamin D level).
  7. Kusama M, Miyauchi K, Aoyama H, et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. — Breast Cancer Res Treat. 2004;88(1):1-8. PMID 15538040.Title and cohort (toremifene vs tamoxifen, both drugs directly studied) confirmed via metadata; full abstract text not retrievable during this review (abstract_inverted_index null in OpenAlex, PubMed abstract page blocked by reCAPTCHA). Cited at title level only, disclosed as such, not used for quantitative claims.
  8. Erkkola R, Mattila L, Powles T, Heikkinen J, Toivola B, Korhonen P, Mustonen MVJ. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. — Breast Cancer Res Treat. 2005;93(3):277-287. PMID 16172794.Title and journal confirmed via metadata; full abstract text not retrievable (abstract_inverted_index null; PubMed abstract page and a guessed Springer DOI both blocked/failed during this review). Cited at title level only, not used for quantitative claims.
  9. Chi F, Wu R, Zeng Y, Xing R, Liu Y, Xu Z. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis. — Breast Cancer. 2013. PMID 23266963.Title/snippet only, via PubMed search-listing page ("toremifene associated with greater decrease in serum triglyceride"); individual abstract page blocked by reCAPTCHA, not independently opened, not used beyond disclosed title-level framing.
  10. Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer. — J Clin Oncol. 2008;26(11):1808-1812. PMID 18398147. Different population (men, androgen-deprivation therapy for prostate cancer) than toremifene's labeled breast cancer indication.Title/snippet only ("LDL cholesterol decreased by 8.2%"); individual abstract page not independently opened, not used for quantitative claims beyond this disclosed snippet.
  11. Anan K, Mitsuyama S, Yanagita Y, et al. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females. — Breast Cancer Res Treat. 2011. PMID 21638048.Title/snippet only via PubMed search listing; individual abstract page not independently opened, not used for quantitative claims.
  12. Hirsimäki P, Hirsimäki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. — Arch Toxicol. 1993;67(1):49-54. PMID 8452480. Rat, 1-year, directly compares tamoxifen and toremifene (both confirmed in cohort via indexed metadata).Cohort confirmed (both drugs studied) but full abstract text not retrievable (abstract_inverted_index null). Not used as supporting evidence for any graded entry; mentioned only in the Mitochondrial burden entry as disclosed, unused context, alongside the FDA label's own, materially different 2-year rat carcinogenicity finding.
  13. Independently re-verified tamoxifen-class source: gut microbiome cohort study. — Prospective cohort, 62 postmenopausal ER+/HER2- breast cancer patients, 3 Dutch hospitals, tamoxifen (not toremifene) before/during therapy. PMC11885672. Re-opened directly in this review; used only for the toremifene Gut microbiome risk entry as an explicitly disclosed class extrapolation, not as toremifene-specific evidence.
  14. Independently re-verified tamoxifen-class source: systemic oxidative-stress/antioxidant study. — Prospective human study, n=64 postmenopausal women with breast cancer, tamoxifen 10 mg twice daily, 6 months; malondialdehyde decreased, serum selenium and vitamins A/C/E increased. Cancer. 1994. PMID 8004586. Re-verified at abstract level via this review's own search process (not cited secondhand from another dossier); used only in the toremifene Oxidative stress entry as a disclosed point of contrast, not as toremifene-specific evidence.Individual PubMed abstract page blocked by reCAPTCHA during this review; direction and key figures taken from this project's independently-conducted search-listing snippets and cross-checked against the already-published tamoxifen dossier's independently-cited figures for consistency, not copied from that dossier as primary evidence.
  15. Buron N, Porceddu M, Loyant R, Martel C, Allard J, Fromenty B, Borgne-Sanchez A. Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals. — Toxicol Sci. 2024;200(2):369-381. DOI 10.1093/toxsci/kfae055. PMID 38676573. Isolated mouse liver mitochondria, 32 steatogenic and 13 nonsteatogenic drugs including toremifene; tri-parametric mtFAO assay plus mitochondrial swelling, transmembrane potential, and reactive oxygen species. Full abstract independently retrieved via OpenAlex this session; toremifene confirmed as one of only four of 45 drugs (with amiodarone, ketoconazole, lovastatin) altering all three secondary mitochondrial parameters. Used in the Mitochondrial burden, Oxidative stress, and ATP production entries.
  16. Cardoso CM, Moreno AJ, Almeida LM, Custódio JB. 4-Hydroxytamoxifen induces slight uncoupling of mitochondrial oxidative phosphorylation system in relation to the deleterious effects of tamoxifen. — Toxicology. 2002;179(3):221-232. DOI 10.1016/s0300-483x(02)00392-x. PMID 12270594. Isolated rat liver mitochondria; tamoxifen-class (not toremifene) comparator used only in the ATP production entry as class-level context.Title, authors, journal, year and DOI independently confirmed via OpenAlex this session; the individual PubMed abstract page returned a reCAPTCHA bot check on every attempt, so the full abstract text (respiratory control ratio, ADP/O ratio, concentration thresholds) was not independently re-verified and is not quoted quantitatively in this dossier.
  17. Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis. — Haematologica, correspondence/letter. Mouse model (Sv129/J, wild-type and Ncoa4-knockout littermates, plus C57BL/6 wild-type), 200 mg/kg tamoxifen (not toremifene) by oral gavage daily for 5 days. Ncoa4-ko mice showed significant RBC/Hb/Hct reduction by day 4; wild-type mice showed the same by day 11, with recovery by day 21. Independently re-opened in full this session (not cited secondhand from tamoxifen's own dossier); used only in the Oxygen delivery/utilization entry as class-level mechanistic context.
  18. Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study. — Gan To Kagaku Ryoho. 1993;20(2). PMID 8422189. Japanese-language journal with English structured abstract. Multicenter, single-arm, dose-finding trial, toremifene 40/60/120/240 mg/day orally, more than 8 weeks, advanced or recurrent breast cancer. Response rates 13.8-40.0% across dose cohorts, no clear dose-response. Adverse events: elevation of GOT/GPT/serum calcium, decrease of hemoglobin, anorexia, nausea/vomiting, fatigue, dizziness, hot flush; moderate grade, reversible, no clear dose-dependency in incidence.English structured abstract independently retrieved via OpenAlex this session; the full Japanese-language article text was not accessed, so no incidence percentage for the hemoglobin decrease specifically is available beyond the qualitative description quoted.
  19. Consumer monographs checked for circulating nutrient-depletion claims (Step 6 audit). — drugs.com/mtm/toremifene.html and rxlist.com/fareston-drug.htm, both accessed 2026-09-26. Neither mentions a vitamin, mineral, or supplement depletion claim for toremifene; both mention only grapefruit juice and St. John's Wort as substances to avoid, and low potassium/magnesium as a contraindication (not a drug effect).
  20. Negative-result and confirming PubMed searches, this revision session (disclosed, not used as evidence beyond what is stated). — Fresh, independently re-run this session, not carried forward from the prior review: toremifene + copper (large unrelated result set); toremifene AND (copper OR cuproptosis OR ceruloplasmin) (blocked by bot check on retry); toremifene AND (iron OR ferritin OR hepcidin OR ferroptosis) (zero results, clean negative); toremifene AND (hemoglobin OR anemia OR hematocrit OR erythropoiesis OR erythroid) (3 results, yielding the PMID 8422189 dose-finding trial used above); toremifene AND (ATP OR "oxidative phosphorylation" OR mitochondrial respiration) (20 results, yielding the Buron et al. 2024 confirmation used above); tamoxifen isolated mitochondria oxidative phosphorylation uncoupling (yielded Cardoso et al. 2002, PMID 12270594).